TTNP vs ORMP vs MNKD vs ABBV

For growth investors, MannKind Corporation (MNKD) is the stronger pick with 22.

2% revenue growth year-over-year, versus -100. 0% for Oramed Pharmaceuticals Inc. (ORMP). AbbVie Inc. (ABBV) offers the better valuation at 85. 0x trailing P/E (14. 2x forward), making it the more compelling value choice. Analysts rate Oramed Pharmaceuticals Inc. (ORMP) a "Buy" — based on 8 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, AbbVie Inc.

(ABBV) is the cheapest at 85. 0x versus MannKind Corporation at 176. 0x.

Over the past 5 years, AbbVie Inc.

(ABBV) delivered a total return of +99. 6%, compared to -93. 4% for Titan Pharmaceuticals, Inc. (TTNP). Over 10 years, the gap is even starker: ABBV returned +293. 8% versus TTNP's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), AbbVie Inc.

(ABBV) is the lower-risk stock at 0. 28β versus Titan Pharmaceuticals, Inc. 's 1. 67β — meaning TTNP is approximately 503% more volatile than ABBV relative to the S&P 500.

By revenue growth (latest reported year), MannKind Corporation (MNKD) is pulling ahead at 22.

2% versus -100. 0% for Oramed Pharmaceuticals Inc. (ORMP). On earnings-per-share growth, the picture is similar: Titan Pharmaceuticals, Inc. grew EPS 29. 4% year-over-year, compared to -435. 7% for Oramed Pharmaceuticals Inc.. Over a 3-year CAGR, MNKD leads at 51. 8% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

AbbVie Inc.

(ABBV) is the more profitable company, earning 6. 9% net margin versus -280. 5% for Titan Pharmaceuticals, Inc. — meaning it keeps 6. 9% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ABBV leads at 32. 8% versus -261. 1% for TTNP. At the gross margin level — before operating expenses — MNKD leads at 82. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for MNKD: 134.

4% to $8. 25.

In this comparison, ABBV (3.

3% yield) pays a dividend. TTNP, ORMP, MNKD do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, AbbVie Inc.

(ABBV) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 28), 3. 3% yield, +293. 8% 10Y return). Titan Pharmaceuticals, Inc. (TTNP) carries a higher beta of 1. 67 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (ABBV: +293. 8%, TTNP: -100. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: TTNP is a small-cap quality compounder stock; ORMP is a small-cap quality compounder stock; MNKD is a small-cap high-growth stock; ABBV is a large-cap income-oriented stock. ABBV pays a dividend while TTNP, ORMP, MNKD do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.